Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1500 participants.

Also called NCT02885857

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,500 participants (planned count) (from the registry)
Sponsor
Chen Xiangmei (from the registry)
Registry
  • NCT NCT02885857
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02885857. Allocation not applicable; no masking; primary purpose treatment. Start 2015-06 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease
Intervention (Drug)
Shenyan Kangfu Tablet
Lead sponsor
Chen Xiangmei (class: other)
Collaborator
Tianjin TongRenTang Group Co., Ltd. (class: not stated)

Record details

Record id
cardio:ct-nct02885857
Content hash
4ee2085f0dfacd9a643eea5693c15965b1a5529f69c47ce58c0b06e4f17533be